These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19007319)

  • 1. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
    Müller N
    Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
    Muller N; Schwarz M
    Neurotox Res; 2006 Oct; 10(2):131-48. PubMed ID: 17062375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.
    Miüller N; Schwarz MJ
    J Neural Transm Suppl; 2007; (72):269-80. PubMed ID: 17982903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA pathology and treatment of schizophrenia.
    Chang HJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5118-26. PubMed ID: 24410561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
    Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
    Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
    Noetzel MJ; Jones CK; Conn PJ
    Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
    Steiner J; Bogerts B; Sarnyai Z; Walter M; Gos T; Bernstein HG; Myint AM
    World J Biol Psychiatry; 2012 Oct; 13(7):482-92. PubMed ID: 21707463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
    Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic drugs for schizophrenia treatment.
    Gibert-Rahola J; Villena-Rodriguez A
    Actas Esp Psiquiatr; 2014; 42(5):234-41. PubMed ID: 25179095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.